Further investigation into the effect of MAPK/ERK, JAK2/STAT3, and PI3k/AKT inhibitors in adipocyte-mediated leiomyoma growth could lead to viable therapeutic strategies for uterine leiomyomas. This evidence concerns the gene JAK2 and uterine corpus leiomyoma.